Last reviewed · How we verify
NCT06922539
ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
Phase 1 trial testing Fenretinide in Small Cell Lung Cancer in 44 participants. Currently enrolling.
1 May 2027
Quick facts
| Lead sponsor | SciTech Development, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 11 December 2025 |
| Primary completion | 1 May 2027 |
| Estimated completion | 1 October 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fenretinide — full drug profile →
- Fenretinide — full drug profile →
Conditions studied
- Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →
Sponsor
SciTech Development, Inc.
Who can join
18 and older, any sex, with Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06922539
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fenretinide
Trials testing the same drug.
- NCT04234048 — Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting
- NCT06181760 — A Study to Evaluate the Safety of Fenretinide in Healthy Volunteers · Phase 1 · completed
- NCT00004154 — Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer · Phase 3 · completed
- NCT00003075 — Fenretinide in Treating Patients With Cervical Neoplasia · Phase 3 · completed
Other recruiting trials for Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
- NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting
- NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
Other SciTech Development, Inc. trials
Trials by the same sponsor.
- NCT04234048 — Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06922539 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SciTech Development, Inc.
- Last refreshed: 15 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06922539.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing